US Patent No: 6,677,155
Number of patents in Portfolio can not be more than 2000
Triple hybrid amplicon vector systems to generate retroviral packaging lines
Stats
-
Jan 13, 2004
Issued date -
Apr 21, 2000
filing date -
09/557,910
serial no -
In Force
status
Importance
Loading Importance Indicators...
Abstract
The present invention relates to a triple hybrid vector amplicon system comprising genetic elements derived from Herpes Simplex Virus (HSV), Epstein-Barr Virus (EBV) or Adeno-Associated Virus (AAV), and a retrovirus. The vector was developed to stably transform cells, both in culture or in vivo, into retrovirus packaging cells in a single step. This step can be accomplished both by transfection using liposomes, electroporation, calcium phosphate, or any other methodology used to transfer naked or complexed DNA into cells or by infection when the vector is packaged as an amplicon vector in HSV virions.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
International Classification(s)
Cited Art
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 5,741,486 Safe vectors for gene therapy | 27 | 1995 | |
|
|
|||
| 5,631,236 Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk | 74 | 1993 | |
|
|
|||
| 5,670,488 Adenovirus vector for gene therapy | 106 | 1993 | |
|
|
|||
| 5,830,727 Herpes simplex virus amplicon mini-vector gene transfer system | 19 | 1995 | |
|
|
|||
| 5,691,177 Recombinant retroviruses expressing a protein that converts a pro-drug into a cytotoxic agent | 43 | 1995 | |
|
|
|||
| 5,830,725 Rapid, stable high-titre production of recombing retrovirus | 26 | 1995 | |
|
|
|||
| 5,688,773 Method of selectively destroying neoplastic cells | 24 | 1994 | |
|
|
|||
| 5,529,774 In vivo transfer of the HSV-TK gene implanted retroviral producer cells | 41 | 1991 | |
|
|
|||
| 5,756,283 Method for improved production of recombinant adeno-associated viruses for gene therapy | 50 | 1995 | |
|
|
|||
| 5,763,217 Method of using, process of preparing and composition comprising recombinant herpesvirus vectors | 17 | 1995 | |
|
|
|||
| 5,763,242 Method for increasing transduction efficiency of recombinant retroviral vectors | 5 | 1995 | |
|
|
|||
| 5,601,818 Cancer therapy utilizing malignant cells expressing HSV-TK | 21 | 1994 | |
Patent Citation Ranking
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jul 13, 2015 |
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |